Pharmacorp Rx increases bought deal offering to $20M

Executive Summary

• Pharmacorp Rx Inc. has entered into an amended agreement to complete an upsized bought deal public offering of 47.7 million units for aggregate gross proceeds of C$20.0 million.
• The offering was driven by strong investor demand, increasing the size from previous indications, with underwriters co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Ltd.
• Net proceeds will be utilized for future acquisition opportunities and general working capital requirements.

Key Details

• Transaction Structure: Bought deal public offering via prospectus supplement to the company's short form base shelf prospectus dated Oct. 14, 2025.
• Units Sold: 47.7 million units.
• Price: C$0.42 per unit.
• Gross Proceeds: C$20.0 million.
• Underwriters: Syndicate co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Ltd.
• Composition of Units: Each unit consists of one common share and one-half of one common share purchase warrant.
• Warrant Terms: Each whole warrant entitles the holder to acquire one common share at an exercise price of C$0.50 per share.
• Warrant Expiration: 24 months from the closing date.
• Use of Proceeds: Future acquisition opportunities and general working capital requirements.
• Closing Date: Expected on or about Nov. 12, 2025, subject to regulatory approvals (including TSX Venture Exchange) and formal documentation.
• Overallotment Option: Underwriters granted an option to purchase up to 15% of the units sold (approx. 7.155 million additional units) to cover overallotments and for market stabilization, exercisable up to 30 days following the closing date.
• Regulatory Filings: Prospectus supplement and base shelf prospectus filed with securities commissions in Canadian provinces (except Quebec); available on SEDAR+.

Notable Quotes

• No direct quotes from management were included in the provided text.